Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00781261
Other study ID # 570989
Secondary ID
Status Recruiting
Phase Phase 2
First received October 27, 2008
Last updated January 11, 2013
Start date August 2009
Est. completion date December 2013

Study information

Verified date January 2013
Source University of Sydney
Contact Monique Macara
Phone +61294631888
Email monique.macara@sydney.edu.au
Is FDA regulated No
Health authority Australia: Department of Health and Ageing Therapeutic Goods Administration
Study type Interventional

Clinical Trial Summary

Osteonecrosis of the hip is an important cause of musculoskeletal disability and finding therapeutic solutions has proven to be challenging. Osteonecrosis means death of bone which can occur from the loss of the blood supply or some other means. Although any age group may develop osteonecrosis, most patients are between 20 and 50 years old. The most common risk factor is a history of high steroid treatment for some medical condition. The next most common associated condition is a history of high alcohol use. There are some cases of osteonecrosis that occur in patients that are otherwise completely healthy with no detectable risk factors.

In the earliest stage of the disease, x-rays appear normal and the diagnosis is made using MRI. The advanced stages of osteonecrosis begin when the dead bone starts to fail mechanically through a process of microfractures of the bone. As the disease progresses, the surface begins to collapse until, finally the integrity of the joint is destroyed. A wide range of surgical treatments with variable success rates have been proposed for the treatment of the osteonecrosis to preserve joint integrity, including core decompression, whereby the venous hypertension that ensues is lessened and revascularisation may be induced leading to bone repair. Nonsurgical treatment options are limited and usually result in a poor prognosis. Early stage disease can be treated with protected weight bearing and physiotherapy, however some studies have shown protected weight bearing to be associated with a greater than 85% rate of femoral head collapse. Unfortunately most studies indicate that the risk for disease progression is greater with nonsurgical treatment than with surgical intervention. There are no established pharmaceuticals for the prevention of treatment of osteonecrosis. Evidence is increasing that the nitrogen containing bisphosphonates may be beneficial in the treatment of osteonecrosis. One bisphosphonates (alendronate) has been evaluated in 60 patients diagnosed with osteonecrosis of the hip. Recent clinical studies have shown very promising results. All patients had symptomatic improvement after one year. Although the follow up time ranged from 3 months to 5 years, only 6 patients progressed to the point of needing surgery.


Description:

Osteonecrosis (ON) of the hip is an important cause of musculoskeletal disability and finding therapeutic solutions has proven challenging. Patients who are affected with ON are often relatively young, usually in the third to sixth decade of life. ON of the hip is an increasingly common cause of musculoskeletal disability. It can cause pain with or without loss of function of the joint and often ends in substantial use of health care resources and disability. ON of the hip usually progresses to severe destruction of the femoral head with resultant degeneration of the hip joint, in most cases requiring joint replacement.

Early diagnosis has been made easier using magnetic resonance imaging (MRI), however no common satisfactory therapy has been developed for the early stage of the disease. Early surgery aimed at preserving the femoral head has been proposed, such as vascularised fibula grafting. However, the results of this invasive technique do not seem to be widely reproducible, and more minor interventions such as core drilling have high failure rates. Evidence is increasing that the nitrogen containing bisphosphonates may be beneficial in the treatment of ON. Data from clinical trials with patients with ON of the hip suggested that the bisphosphonate alendronate would reduce pain and disability and may reduce progression to femoral head collapse that usually would require surgical intervention.

With this study we aim to determine the efficacy of bisphosphonate therapy (zoledronic acid) versus placebo for reducing pain and disability in ON of the femoral head necrosis (palliative endpoint) and to investigate the effect of bisphosphonate therapy versus placebo in reducing progression to femoral head collapse and the need for surgical intervention (therapeutic endpoint).

Methods This will be a 2-armed double-blind randomised trial of a) zoledronic acid 5mg annually for 3 doses b) placebo drug infusions. Participants will be recruited primarily from rheumatologists and orthopaedic surgeons from multiple centres in Australia. We plan to include 4 major centres in capital cities in Australia and each centre would recruit approximately 30 participants. Potential participants who meet the eligibility criteria will be identified by their treating Rheumatologists or Orthopaedic surgeons, followed by a screening assessment conducted by the study research staff. Eligible participants will be randomised prior to the start of treatment. Prior to treatment, the study research staff will perform a baseline assessment over the phone, including demographic details, age, sex, duration of symptoms, medical history including prior surgery, trauma and medication use and known risk factors for ON. Furthermore at baseline, the Rheumatologists or Orthopaedic surgeon will perform a clinical evaluation using a slightly modified Harris Hip Score (HHS). The study research staff will contact the participants every 6 months to monitor the participant's condition and evaluate pain and disability. Additionally the participants will have a clinical evaluation and MRI scan at 12 months.

This novel clinical research protocol will aim to provide further evidence of the protective value of alendronate or zoledronic acid in patients with ON of the hip. It will determine whether bisphosphonates slow the progression of symptoms as well as the progression to total collapse of the hip. Additionally it will seek to answer questions regarding the comparative effectiveness and also cost-effectiveness of the use of bisphosphonates in early disease. The results of this study can lead to change in treatment of early disease ON and delay and possibly prevent surgical intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

1. aged between 18-90 years,

2. symptoms of pain and disability in at least one hip joint, or

3. positive MRI findings stage I or II on the ARCO classification

Exclusion Criteria:

1. previous hip joint surgery on the affected hip

2. severe pain and disability at rest if treating clinician has recommended surgery

3. radiographic or MRI findings suggestive for stage III and IV on the ARCO classification

4. any iv bisphosphonate within the prior 2 years or any prior use of bisphosphonate preparations, except according to the washout schedule:

- 2 years (if use > 48 weeks),

- 1 year (if used > 8 weeks but < 48 weeks)

- 6 months (if used > 2 weeks but < 8 weeks)

- 2 months (if used < 2 weeks)

5. active primary hyperparathyroidism

6. hypothyroidism, not appropriately controlled with long-term thyroxine therapy

7. history of iritis or uveitis, except due to trauma, and resolved for > 2 years prior to study

8. self-reported history of diabetic nephropathy or retinopathy (if diabetic, Hb A1c > 10%)

9. urine dipstick greater than or equal to 2+ protein at screening

10. AST or ALT greater than twice the upper limit of normal and/or alkaline phosphatase greater than twice the upper limit of normal

11. serum calcium > 2.75 mmol/L (11.0 mg/dL) or < 2.00 mmol/L (8.0 mg/dL)

12. serum 25-hydroxyvitamin D concentrations < 15 ng/L m) baseline renal insufficiency (calculated creatinine clearance less than 40 mL/min and serum creatinine greater than 175 mol/L) at V1

13. a history of invasive malignancy of any organ system, treated or untreated, in the past five years; excluding, basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed, ductal carcinoma in-situ (DCIS), and carcinoma in-situ (CIS) of the uterine cervix

14. any candidate patient with severe dental problems or current dental infections and/or any candidate patient with recent or impending dental surgery within three months of dosing

15. women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Zoledronic Acid
Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
Placebo
Subjects in the control group will receive a placebo drug for a similar period

Locations

Country Name City State
Australia The Queen Elizabeth Hospital Adelaide South Australia
Australia Princess Alexandra Hospital Brisbane Queensland
Australia Royal Brisbane and Womens Hospital Herston Queensland
Australia Cabrini Hospital Melbourne Victoria
Australia Royal North Shore Hospital, Department of Rheumatology Sydney New South Wales

Sponsors (2)

Lead Sponsor Collaborator
University of Sydney Novartis

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary reducing pain and disability in the hip 1 years No
Secondary reducing progression to femoral head collapse and the need for surgical intervention 3 years No
See also
  Status Clinical Trial Phase
Terminated NCT04072055 - MOTO Post-marketing Surveillance Study
Terminated NCT02941666 - Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip
Terminated NCT01763684 - Oxford Signature vs. Conventional Global Study N/A
Completed NCT00505219 - Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head Phase 3
Withdrawn NCT02632903 - Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study Phase 2
Active, not recruiting NCT01458782 - ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee N/A
Completed NCT01583465 - Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty N/A
Active, not recruiting NCT04401267 - Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma Phase 2
Completed NCT03197623 - Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids Phase 1
Active, not recruiting NCT05283148 - Sickle Cell Disease (SCD) Bone Pain Study N/A
Completed NCT05684588 - Post-COVID-19 Sequelae: Osteonecrosis of Femoral Head N/A
Terminated NCT03269409 - Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis Phase 1
Completed NCT00913679 - A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty N/A
Enrolling by invitation NCT02893293 - Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI Phase 4
Completed NCT01345097 - A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients Phase 4
Recruiting NCT00260897 - Molecular Genetic Study of Avascular Necrosis of the Femoral Head N/A
Not yet recruiting NCT06016634 - Alendronate for Osteonecrosis in Adults With Sickle Cell Disease Phase 2
Completed NCT02077647 - Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee
Recruiting NCT01619124 - Osteonecroses in Pediatric Patients With ALL N/A
Completed NCT02458937 - Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis